Information for the public

Daratumumab (Darzalex) is available through the Cancer Drugs Fund as a possible treatment for relapsed or refractory multiple myeloma in adults if:

  • they have already had 3 other therapies (including a proteasome inhibitor and an immunomodulator) and
  • their disease has progressed on the last therapy.

More evidence on daratumumab is being collected, until November 2020. After this NICE will decide whether or not to recommend daratumumab for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.

If you are not eligible for daratumumab but are already taking it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about making decisions about your care.

Questions to think about

  • How well does it work compared with other treatments?
  • What are the risks or side effects? How likely are they?
  • How will the treatment affect my day-to-day life?
  • What happens if the treatment does not work?
  • What happens if I do not want to have treatment? Are there other treatments available?

Information and support

NHS Choices may be a good place to find out more

These organisations can give you advice and support:

You can also get support from your local Healthwatch.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2868-2


This page was last updated: 14 March 2018